Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status

Due to the high variance in response rates concerning anti-PD1 immunotherapy (IT), there is an unmet need to discover innovative biomarkers to predict immune checkpoint inhibitor (ICI)-efficacy. Our study included 62 Caucasian advanced-stage non-small cell lung cancer (NSCLC) patients treated with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dora, David, Ligeti, Balazs, Kovacs, Tamas, Revisnyei, Peter, Galffy, Gabriella, Dulka, Edit, Krizsán, Dániel, Kalcsevszki, Regina, Megyesfalvi, Zsolt, Dome, Balazs, Weiss, Glen J., Lohinai, Zoltan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184596/
https://www.ncbi.nlm.nih.gov/pubmed/37197440
http://dx.doi.org/10.1080/2162402X.2023.2204746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184596/
https://www.ncbi.nlm.nih.gov/pubmed/37197440
http://dx.doi.org/10.1080/2162402X.2023.2204746

Ejemplares similares